SymBio Pharmaceuticals Limited

Tokyo Stock Exchange 4582.T

SymBio Pharmaceuticals Limited EBITDA Margin for the year ending December 31, 2023: -12.77%

SymBio Pharmaceuticals Limited EBITDA Margin is -12.77% for the year ending December 31, 2023, a -157.99% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

SymBio Pharmaceuticals Limited EBITDA Margin for the year ending December 31, 2022 was 22.03%, a 63.76% change year over year.
SymBio Pharmaceuticals Limited EBITDA Margin for the year ending December 31, 2021 was 13.45%, a 109.04% change year over year.
SymBio Pharmaceuticals Limited EBITDA Margin for the year ending December 31, 2020 was -148.72%, a 1.01% change year over year.
SymBio Pharmaceuticals Limited EBITDA Margin for the year ending December 31, 2019 was -150.24%, a -119.83% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

Tokyo Stock Exchange: 4582.T

SymBio Pharmaceuticals Limited

CEO	Mr. Fuminori Yoshida
IPO Date	Oct. 20, 2011
Location	Japan
Headquarters	Toranomon 30 Mori Building
Employees	109
Sector	Healthcare
Industries Clinical Trials 3D Printing Biotechnology Non-Alcoholic Beverages Pharmaceuticals Vaccines

Description

SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and marketing of pharmaceutical drugs in the areas of oncology and hematology in Japan. It is involved in the development of Treakisym SyB L-0501, an anti-cancer agent, which is marketed for the treatment of non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia under the TREAKISYM name; and is in the Phase III clinical trial to treat relapsed/refractory diffuse large B-cell lymphoma. The company also engages in the development of SyB L-1701, a ready-to-dilute formulation; and SyB L-1702, a rapid infusion liquid formulation. In addition, it is involved in the development of SyB L-1101, an intravenous formulation, which is in Phase III clinical trial for the treatment of higher-risk myelodysplastic syndromes (HR-MDS); and SyB C-1101, an oral formulation that is in Phase II/III clinical trial in combination with Azacitidine to treat HR-MDS. Further, it engages in the development of SyB V-1901, an antiviral drug for the treatment of infectious diseases. SymBio Pharmaceuticals Limited was incorporated in 2005 and is based in Tokyo, Japan.

Key trends

Past 5 years